Trial Eligibility
Have you or someone you know been diagnosed with non-obstructive hypertrophic cardiomyopathy (nHCM)?
ACACIA-HCM
ACACIA-HCM is currently recruiting participants to evaluate the safety and efficacy of an investigational drug for Non-obstructive Hypertrophic Cardiomyopathy (nHCM).
ACACIA-HCM is a phase 3 placebo-controlled clinical trial researching the investigational drug called aficamten.
Who
People diagnosed with nHCM and who are experiencing symptoms of HCM.
Where
Site locations are within the United States; this website is limited to providing information related to sites in this country. For more information, please visit clinicaltrials.gov/study/NCT06081894.
Travel Expenses
Volunteers who qualify to take part in the study may receive compensation for study-related travel expenses.
Aficamten is an investigational drug and is not currently approved for use by regulatory agencies like the FDA – its safety and effectiveness has not been established.